 |
December 17, 2009
Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 in Patients with Glioblastoma Multiforme (GBM) more »
December 15, 2009
Arno Therapeutics Announces Poster Presentation at ASH Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity of AR-42 more »
August 27, 2009
Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway more »
|
 |
Ohio State University cancer researchers are recruiting patients to a phase I clinical trial for a new drug designed to inhibit the growth of solid tumors. The phase I clinical trial will assess the safety and early evidence of activity of AR-12 » Read
The Ohio State University
Potential cancer therapies invented at Ohio State are licensed to drug development firm. » Read
2008 AACR Annual Meeting, April 12-16, 2008, San Diego, CA
» Search abstracts
|
|
